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Abstract 26 
Bifidobacterium breve is one of the dominant Bifidobacterial species in children. 27 
In the current work, 46 strains of B. breve isolated from fecal samples of Chinese 28 
children were analyzed using whole-genome sequencing and comparative genomics 29 
to explore their genetic diversity, as well as genotype and phenotype analysis for 30 
carbohydrate utilization and antibiotic tolerance. The phylogenetic tree was 31 
independent of region, age and feeding mode, and without any regularity in the 32 
clustering of carbohydrates and antibiotics at the g netic level. Based on 33 
genotypic-phenotypic correlation analysis, the diversity of glycosyl hydrolases and 34 
the ability of strains to metabolize carbohydrates corroborated the predominance of B. 35 
breve in the children’s intestines. Simultaneously, the snsitivity of strains to 36 
antibiotics increased the understanding of its genetic f atures and provided a potential 37 
basis for safety evaluation. 38 
Keywords: Bifidobacterium breve; comparative genomics; carbohydrate metabolism; 39 
antibiotic resistance; genomic diversity  40 
1. Introduction 41 
Bifidobacterium is one of the commensal microorganisms in the colon and one of the 42 
first bacterial colonizers to settle in the human intestine after birth, which has been 43 
related to maintaining intestinal health (Arboleya et al., 2016). The beneficial effects 44 
of Bifidobacteria include intestinal barrier reinforcement, pathogen inhibition, 45 
immune system modulation and nutrient supplementation as well as host metabolism 46 
enhancement and expansion (Round and Mazmanian, 2009; Tojo et al., 2014; Ventura 47 
et al., 2012). In infants especially in neonates, Bifidobacteria, particularly 48 
Bifidobacterium breve, B. longum and B. bifidum, made up a large proportion of gut 49 
microbes (Turroni et al., 2018). 50 
B. breve is not only a commonly encountered species in the fec s of infants, and also 51 
has been frequently isolated from human milk and the vagina. The species represents 52 
one of the most extensively researched Bifidobacteria in terms of comparative and 53 
functional genomics investigations. Since genome sequence of B. breve UCC2003 54 
was published first among the species in 2011, a number of other B. breve genomes 55 
have been sequenced and publically available (Jin et al., 2019). 56 
The successful adaptation of B. breve to ecological niches is related to its 57 
saccharolytic catabolism. B. breve could utilize plant-saccharides, polysaccharides, 58 
oligosaccharides, and monosaccharides, which reflects flexibility of carbohydrate 59 
utilization (Pokusaeva et al., 2011a). Carbohydrate utilization may be correlated with 60 
the niche of some strains, e.g., some B. breve strains isolated from breast-fed infants 61 
showed the ability to metabolize 2’-fucosyllactose (2’-FL), which is the dominant 62 
glycan component among human milk oligosaccharides (HMOS) (Castanys-Muñoz et 63 
al., 2013). In addition, Bifidobacteria are used in fu ctional foods and medicines as a 64 
probiotic. Safety issues related to antibiotic resistance are of concern (Francino, 2015). 65 
Gene-trait matching could serve as an effective approach to elucidate genes 66 
responsible for a specific phenotype using a combinatio  of comparative genome 67 
analysis and experimental data, such as carbohydrate metabolism and antibiotic 68 
resistance (Bottacini et al., 2018). The aim of the current study was to analyze the 69 
genomic diversity of B. breve isolated from Chinese children, and to further compare 70 
their carbohydrate utilization and antibiotic resistance both genotypically and 71 
phenotypically. Those analyses may help better understand the physiological 72 
properties and metabolic characteristics of different B. breve strains to guide the 73 
screening and application of particular strains (Boesten et al., 2011). 74 
2. Materials and methods  75 
2.1 Isolation and 16S rRNA sequence analysis 76 
Eighty children’s stool samples from different regions of China were collected (Table 77 
1). One g of each stool sample was blended with 9 mL sterile physiological saline 78 
(Bottacini et al., 2018). Serial dilution and plating were done using an anaerobic 79 
workstation (AW400TG, Electrotek Scientific Ltd., Shipley, West Yorkshire, UK). For 80 
selection of Bifidobacteria, 100 μL of diluent was continuously plated on de 81 
Man-Rogosa-Sharpe agar (Qingdao Hope Bio-Technology Co. Ltd., Qingdao, 82 
Shandong, China) plus 0.05% (v/w) L-cysteine hydrochl ride (Sangon Biotech Co., 83 
Ltd., Shanghai, China) (MRSC) plus 100 mg/L mupirocin (Sangon Biotech Co., Ltd.) 84 
and 50 U/mL nystatin (Sangon Biotech Co., Ltd.). Agar plates were cultured in the 85 
anaerobic workstation flushed with 80% N2, 10% CO2 and 10% H2 at 37 °C for 72 h 86 
(Bottacini et al., 2018). For each sample, colonies on MRSC plates were counted. 87 
Colonies were selected randomly and re-streaked onto MRSC agar for purity. The 88 
final pure culture was cultured in MRSC and preserved in 30% glycerol (Sangon 89 
Biotech Co., Ltd.) at -80 °C (Bottacini et al., 2018). Each of the possible 90 
Bifidobacteria isolates was identified by a 16S rRNA sequence using the bacterial 91 
universal primers (27F: 5’-AGA GTT TGA TCC TGG CTC AG-3’ and 1492R: 92 
5’-ACG GCT ACC TTG TTA CGA CTT-3’). PCR amplification conditions were: 93 
95 °C for 8 min; 95 °C for 40 s, 60 °C for 40 s, 72 °C for 40 s, 30 cycles; 72 °C for 8 94 
min (Boesten et al., 2011). The PCR product was sequenced by BGI (Shenzhen, 95 
Guangdong, China). All the strains were compared with the NCBI BLAST database 96 
(http://www.ncbi.nlm.nih.gov/BLAST/) to assign a particular species. 97 
2.2 Sequencing and draft genome assembly 98 
Draft genomes of all the 46 B. breve strains were sequenced using an Illumina Hiseq 99 
× 10 platform (Majorbio BioTech Co., Ltd., Shanghai, China), with the use of 2 × 150 100 
bp paired-end libraries (average read length of ~400 bp). The assembly was done 101 
using SOAPdenovo v2.04 software (https://omictools.c m/soapdenovo-tool), and the 102 
partial gap was filled by GapCloser 103 
(https://sourceforge.net/projects/soap-denovo2/files GapCloser/) (Liu et al., 2013; 104 
Zerbino and Birney, 2008). 105 
2.3 General features prediction 106 
Bacterial gene prediction and open reading frames (ORFS) were done using Glimmer 107 
3.02 software (http://ccb.jhu.edu/software/glimmer/index.shtml), GeneMarkS v4.30 108 
software (https://www.genemarks.com/) (Rice et al., 2000) and the predictor Prodigal 109 
v2.0 software (http://prodigal.ornl.gov). BLASTX v2.2.26 alignment 110 
(ftp://ftp.ncbi.nlm.nih.gov/blast/executables/LATEST) was carried out for all the 111 
genomes analyzed (Patel and Jain, 2012). The tRNA genes in the genome were 112 
predicted using tRNAscan-SE v1.3.1 software (https://omictools.com/trnascan-se-tool) 113 
(Schattner et al., 2005). 114 
2.4 Comparative genome analysis 115 
All-versus-all BLASTP alignment (50% identity; E-value 1e-4 cut-off) was done for 116 
protein sequences extracted from each strain (Enright et al., 2002). BLAST outputs 117 
served as inputs to cluster into families of proteins sharing the same function using the 118 
Markov Cluster Algorithm (MCL) with an inflation index of 2.5 119 
(https://micans.org/mcl/) (Goris et al., 2007). The gene families obtained were divided 120 
into core genome or dispensable genome, based on their existence in all or in a subset 121 
of the strain investigated. To calculate ANI values for each pair of genomes, an ANI 122 
Perl script was implemented (https://github.com/chjp/ANI/blob/master/ANI.pl) (Qin 123 
et al., 2014). 124 
2.5 Pan-genome and core-genome analysis 125 
To predict possible dynamic changes in the genome, the size of the pan-genome, core 126 
genome and unique genes were calculated. Computation of pan-genome and 127 
core-genome was done using PGAP v1.2.1 software 128 
(https://sourceforge.net/pro-jects/pgap/files/PGAP-1.2.1) (Zhao et al., 2012) in 129 
accordance with the Heap’s law pan-genome model (Zhao et al., 2012). Among them, 130 
amino acids had 50% pairwise identity and a 0.7 length difference cut-off threshold 131 
(Harris et al., 2017). Then the Venn diagram was drawn to show the relationships 132 
between samples. 133 
2.6 Phylogenetic analyses 134 
The homologous genes for all of the 46 strains sequenced, in addition to 9 publicly 135 
available B. breve genomes, as well as two B. bifidum and one B. longum genomes 136 
from the NCBI GenBank database were analyzed based on Orthomcl v2.0.9 software 137 
(http://orthomcl.org/common/downloads/software/v2.0/) (Liu and Warnow, 2014). 138 
After extraction of orthologous genes, MAFFT alignment was done using 139 
MAFFT-7.313-with-extensions (https://mafft.cbrc.jp/alignment/software) (Divakar 140 
and Crespo, 2015), and finally phylogeny was used to generate a phylogenetic tree. 141 
2.7 Genotype and phenotype of carbohydrate utilization of B. breve species 142 
All the genomes were annotated using the HMMSCAN software (hmmer.org) (Tong 143 
et al., 2017) in combination with BLASTP. The carbohydrate active enzyme gene 144 
profiles were analyzed and compared using the carbohydrate-active enzymes (CAZy) 145 
database (http://www.cazy.org/). Cluster analysis was done using HEMI software 146 
(hemi.biocuckoo.org). 147 
Twenty carbohydrates including D-lactose, D-ribose, glucose, FOS, maltose, 148 
D-galactose, raffinose, α-L-fucose, D-sorbitol, D-mannitol, D-fructose, sucrose, 149 
cellobiose, soluble starch, L-arabinose, D-glucuronate, XOS, 2’-FL, trehalose and 150 
D-xylose were further selected for carbohydrate utilization analysis, and all the sugars 151 
were purchased from Sangon Biotech Co. Ltd. A 10% (v/w) fresh solution of those 152 
carbohydrates was prepared and filtered through a 0.22 μm sterile membrane filter 153 
(Saigon Biotech Co. Ltd.). The utilization assay medium was freshly prepared with 154 
the same content as MRSC medium except 2% glucose, and bromcresol purple as an 155 
indicator (Sangon Biotech Co. Ltd.) were added intothe medium. After autoclaving 156 
and cooling, each of the sterile carbohydrates solutions were added into the medium at 157 
1% final concentration. To test the utilization capacity of each strain, after 158 
sub-culturing twice in MRSC medium, a 1% culture was inoculated into the test 159 
growth media which was supplemented with a different sugar instead of glucose, and 160 
cultured anaerobically at 37 °C for 48 h (Arboleya et al., 2018). Color changes were 161 
observed and growth was measured using a microplate reader (Varioskan Lux, 162 
Thermo, Waltham, MA, USA) at OD600nm. All the tests were done in triplicate. 163 
2.8 Genotype and phenotype of antibiotics resistance among B. breve species 164 
The antibiotic-resistant genes were analyzed using the comprehensive antibiotic 165 
resistance database (CARD) (https://card.mcmaster.ca) to obtain information of 166 
predicted antibiotic resistance genes encoded by each genome. Cluster analysis was 167 
done with HemI software (hemi.biocuckoo.org) (Masco et al., 2006). 168 
According to ISO10932:2010 standard “Milk and milk products-determination of the 169 
minimal inhibitory concentration (MIC) of antibiotics applicable to bifidobacteria and 170 
non-enterococcal lactic acid bacteria (LAB)” 171 
(http://www.iso.org/iso/iso_cata-logue/catalogue_tc/catalogue_detail.htm?csnumber=172 
46434)”, the MIC value of 6 antibiotics (streptomycin, erythromycin, clindamycin, 173 
chloramphenicol, tetracycline, and trimethoprim) (Saigon Biotech Co. Ltd.) were 174 
analyzed for all the strains. Microbial dilutions were incubated under anaerobic 175 
conditions at 37 °C for 48 h, and finally the absorbance at OD625nm was measured with 176 
the microplate reader. 177 
 178 
3. Results 179 
3.1 Strains isolation and their general genome features 180 
A total of 400 isolates were obtained from the Bifidobacterial selective agar, and all of 181 
them were identified for species using 16S rRNA sequence. Among them, 93 isolates 182 
from 46 samples were confirmed as B. breve. Other than FFGZ18I1M1 and 183 
FFGZ18I1M6, FFGZ19I1M4 and FFGZ19I1M6, only one B. breve strain isolate from 184 
each sample was used for genome sequencing (Table 1).  185 
The draft genome of those isolates were sequenced using an Illumina Hiseq platform 186 
and subjected to further analysis with another 9 publicly available B. breve genomes 187 
(https://www.ncbi.nlm.nih.gov/genome/genomes/1273), corresponding to B. breve 188 
UCC2003 (O’Connell-Motherway et al., 2011b), B. breve 12L, B. breve 31L, B. breve 189 
CECT7263 (Jiménez et al., 2012), B. breve NCFB2258, B. breve ACS071VSCH8b, B. 190 
breve 689b, B. breve S27 and B. breve JCM7017 (Bottacini et al., 2015). The number 191 
of predicted ORFS of each genome ranged from 1748 for B. breve S27 to 2396 for 192 
FJSWX26M5. On average, 2024 ORFS were identified/genome. The average 193 
genomic size was 2.33 Mb, with FFHNXY43M2 being thesmallest genome (2.16 194 
Mb), and FJSWX26M5 the largest (2.64 Mb). The sequence and assembly results for 195 
those strains generated a number of contigs/genome that ranged from 1 to 521. The 196 
average G+C% content of all the B. breve was 58.8±0.5%, and those strains consisted 197 
of 51-75 tRNA genes distributed across the genomes (Table 1). 198 
3.2 Comparative analyses 199 
Comparative genome analyses based on 55 genomes of B. breve showed the 200 
emergence of shared orthologous genes and unique genes. Using BLASTP-mediated 201 
comparative genomics methods in conjunction with the use of the MCL algorithm, the 202 
results were able to describe a pool of 1,150 gene families shared by those 55 203 
genomes, thereby allowing the determination of the predicted core genome (Fig. 1A). 204 
Core genes accounted for ~28% of the total gene families. The remaining were 205 
presumed to represent the dispensable genome, which indi ated the genomic diversity 206 
among B. breve species (Fig. 1B, 1C). 207 
Additionally, the dispensable-gene results showed the presence of 1,411 unique or 208 
strain-specific genes, of which 1,244 genes were present in the 46 B. breve draft 209 
genomes (Fig. 1A). The number of dispensable genes ranged from 108 genes in 210 
FFHNFQ49M1 to three genes in FFGZ19I1M4, and most of he genes observed 211 
within the distributable genomes reflected the high diversity among B. breve strains. 212 
The in silico method was applied to predict the average nucleotid identity (ANI) 213 
value of B. breve genomes, and the correlation of ANI values ranged from 97 to 99%, 214 
indicating that all those strains belonged to the same species without any potential 215 
subspecies (Fig. 1D). 216 
3.3 Pan- and core-genome of B. breve 217 
To compute the total number of genes in the B. breve genomes, the PGAP pipeline 218 
was used to do the pan-genome calculation in two steps. First, the pan-genome of all 219 
the 55 B. breve genomes was computed, showing that the pan-genome trendline was 220 
recognized as the total number of gene families. A pan-genome of B. breve consisted 221 
of 6,707 gene families (Fig. 2A). The number of new genes obtained by adding 222 
genomic sequences decreased from 404-100 gene families in the first 14 genome 223 
iterations to 45-41 gene families in the last 9 genome additions, thus showing a 224 
relatively saturated trend of the pan-genome within B. breve species. Second, the 225 
core-genome result tended to be stable after the 22nd genomic iteration, reaching the 226 
value of 1,111 gene families in the last iteration. (Fig. 2A). The functions of the core 227 
genome of B. breve were related to secondary metabolites biosynthesis, transportation, 228 
amino acid and carbohydrate metabolism and transports systems (Fig. 2B). 229 
3.4 Phylogenomic analyses of B. breve 230 
A phylogenomic analysis was done to recognize homolgous genes between strain 231 
genome sequences belonging to the B. breve species and other strains, including 232 
publicly available B. longum and B. bifidum genomes (Fig. 3). B. breve and other 233 
Bifidobacterium species were computed based on 997 orthologues, although they had 234 
large homologous genes, and B. longum combined with B. bifidum as a representative 235 
outgroup. No correlation was evident from the evoluti nary tree within the sampling 236 
regions, neither feeding methods nor age of the donors. FFGZ18I1M1 and 237 
FFGZ18I1M6 were isolated from the same sample. However, they were unable to 238 
cluster together in the phylogenomic tree, and similar results were found for 239 
FFGZ19I1M4 and FFGZ19I1M6, which indicated significantly strain-dependent 240 
genetic difference even from the same gastrointestial tract. 241 
3.5 GH families and carbohydrate utilization phenotype analysis 242 
The saccharolytic enzymes of Bifidobacteria are capable of metabolizing large 243 
amounts of carbohydrates, ranging from dietary-derived to host-derived carbohydrates 244 
(Watson et al., 2013). All the newly sequenced genomes were predicted using the 245 
accordance with the CAZy database in silico. The pan-genome of B. breve species 246 
included 9 glycosyl transferase (GT) families, 9 carbohydrate esterase (CE) families, 247 
13 carbohydrate-binding modules (CBM) families, one polysaccharide lyase (PL) 248 
family (Fig. 4A) and 35 glycosyl hydrolase (GH) families (Fig. 4B). There was no 249 
notable correlations between the sugar metabolism gene representation and the 250 
sampling regions through cluster analysis (Fig. 4B). Members of the GH13 and GH3 251 
family accounted for the largest percentage of GH predicted in the B. breve genome 252 
(24 and 8%, respectively) (Fig. 4B), consistent with a previous study on 253 
Bifidobacterium (Kelly et al., 2006). Members of the GH95 and GH29 families acted 254 
as representatives, participating in the utilization f fucose-containing substrates 255 
(Matsuki et al., 2016). In the current research, in silico analysis showed that genes 256 
encoding for GH29 and GH95 were present on the genom  f a given strain, such as 257 
FFHNFQ4M7, FFHNFQ49M1, FHuNCS1M5, FHuNCS6M1, FJSWX5M4, 258 
FJSWX17M1, FJSWX24M2, FJSWX26M5, FJSWX23M8, FZJHZ3M2 and 259 
FZJHZ7M2, and those strains were mainly isolated from breastfed babies and those 260 
<1 yr.  261 
To evaluate and verify the in silico analyses, 20 carbohydrates were used as a single 262 
carbon source, glucose was used as a positive control for in vitro growth assays. 263 
Comparing carbohydrate utilization of the 46 strains isolated from Chinese children 264 
showed that almost all the strains could utilize D-lactose, maltose and FOS. On the 265 
other hand, the ability to utilize other sugars such as sucrose, soluble starch, 266 
D-glucuronate, 2’-FL, raffinose, D-ribose, trehalose, L-arabinose, cellobiose, 267 
D-xylose, D-galactose, D-fructose, XOS and α-L-fucose varied with strain (Fig. 5). 268 
All the 46 strains showed similar utilization for D-mannitol and D-sorbitol, which was 269 
consistent with a previous report (Bottacini et al., 2018).  270 
In addition, 7 gene clusters related to the utilization of 2’-FL, XOS, D-ribose, 271 
cellobiose, D-mannitol/D-sorbitol, sucrose and D-galactose were identified (Fig. 6). 272 
According to the experimental results, taking FHuNCS6M1 as an example and B.273 
longum APC1477 as a reference strain (Arboleya et al., 2018), the gene cluster for 274 
2’-FL utilization mainly consisted of substrate-bindi g protein (SBP) of an ABC 275 
transporter, two ABC substrate binding proteins and  fucosidase gene (Fig. 6A). 276 
Based on the prediction, the GH43 gene family could encode α-L-arabinofuranosidase 277 
and β-1,4-xylosidase, which could hydrolyze XOS (Arboleya et al., 2018). According 278 
to the combined analysis of genotype and phenotype, FHuNCS6M1 was chosen as 279 
representative to speculate on the mechanism of using XOS (Fig. 6B).  280 
The gene cluster corresponding to the growth of the strain on cellobiose included 281 
genes encoding a ketol-acid reductoisomerase, β-glucosidase, a transcriptional 282 
regulator and a ABC transporter system (Pokusaeva et l., 2011b) (Fig. 6C). 283 
Additionally, only 8 strains could utilize D-ribose as a sole carbon source to grow and 284 
the growth features allowed identification of a gene cluster encoding for a predicted 285 
ribokinase, D-ribose pyranase, a transcriptional regulator, a ribose transporter system, 286 
a predicted hypothetical protein and a MFS transporter (Pokusaeva et al., 2010) (Fig. 287 
6D). As for D-mannitol/D-sorbitol utilization, an important gene cluster consisted of 288 
α-acetolactate decarboxylase, an alcohol dehydrogenase, a hypothetical protein and a 289 
transport system which may be involved (Bottacini et al., 2014) (Fig. 6E). Growth on 290 
D-galactose corresponded to a gene cluster, which in luded genes encoding for 291 
endo-1,4-β-galactosidase, an ABC transporter system and a transc iptional regulator 292 
(O'Connell-Motherway et al., 2011a) (Fig. 6F). With regard to sucrose, a relative gene 293 
cluster composed of β-fructosidases (levanase/invertase), an ABC transporter and a 294 
solute-binding protein (Ryan et al., 2005) were observed (Fig. 6G). 295 
3.6 Resistance gene and phenotype binding analysis 296 
Six different antibiotics were analyzed including ampicillin, gentamicin, tetracycline, 297 
chloramphenicol, ciprofloxacin and vancomycin using gene-trait matching analysis 298 
for the 46 B. breve strains. At the gene level, there was no significant clustering for 299 
the 6 antibiotic-related genes among the strains. All of the strains having a gene 300 
associated with the β-lactam antibiotic, but no significant difference in the number of 301 
resistance genes associated with other antibiotics were obtained (Fig. 7A). For 302 
tetracycline, the tet homologous genes were identified in all of the strains. The 303 
mechanisms underlying resistance to aminoglycosides (such as gentamicin), in which 304 
aminoglycoside phosphotransferase (APH), aminoglycoside adenylyltransferase 305 
(ANT) and N-acetyltransferase (AAC)-related genes were found in the CARD 306 
comment results. The vancomycin genes predicted were vanA, vanB and vanG, which 307 
were seen in most of the strains assessed. In addition, the ampicillin resistance gene 308 
encoded protein, PBP2, which was also in all the strains. The common resistance gene 309 
for chloramphenicol was fexA or cfrA (Kehrenberg and Schwarz, 2004; 2006), which 310 
was found in almost all of those strains. Resistant ge es for fluoroquinolone, gyrA and 311 
parC (Janoir et al., 1996), were found in all those strains. 312 
In phenotypic experiments, B. breve strains showed different sensitivity to those 6 313 
antibiotics, and the MIC varied (Table 2). According to the MIC value of B. longum 314 
ATCC15707, the threshold value of antibiotic tolerance and intolerance was 315 
determined (Fig. 7B). For tetracycline, the MIC values ranged from 0.125 to 64 316 
μg/mL. For gentamicin, strains showed significantly different degrees of tolerance, 317 
thus the MIC ranged from 2 to 256 μg/mL. For vancomycin, a typical glycopeptide 318 
antibiotic, vancomycin-sensitive strains accounted for 76%, only FJSWX17M1, 319 
FBJCP1M6, FFBJHD5M2 and FAHWH9M5 showed a high tolerance, and the MIC 320 
value was 16 μg/mL. Each strain was tested for a gene associated with tolerance to 321 
ampicillin, which was a typical β-lactam antibiotic. The MIC ranged from 0.0625 to 8 322 
μg/mL, while the MIC for chloramphenicol ranged from 0.5 to 32 μg/mL. For one of 323 
the representative fluoroquinolone drugs, the MIC values of ciprofloxacin ranged 324 
from 0.25 to 128 μg/mL among all the strains assessed.  325 
 326 
4. Discussion 327 
B. breve is one of the most abundant species of Bifidobacteria in the gastrointestinal 328 
tract of breast-fed neonates and infants, and their existence is considered helpful 329 
(Bottacini et al., 2018b; Freitas and Hill, 2018). Forty-six strains of B. breve isolated 330 
from Chinese children were used to carry out the genomic diversity analysis within 331 
the species and evaluated their abilities to metabolize different carbohydrates and 332 
resist antibiotics. Draft genomes of 46 strains were sequenced and comparative 333 
genomic analysis was done with other published B. breve genomes. The average G+C% 334 
content of B. longum and B. bifidum was ~60 and 62.7%, respectively (Odamaki et al., 335 
2018; Turroni et al., 2011), while the average G+C% content of B. breve in the current 336 
study was 58.8±0.5%, which was consistent with that in B. longum and B. bifidum, 337 
but inconsistent with published B. breve results (Bottacini et al., 2018). The total 338 
predicted ORFS of each genome varied (ranging from 1,748 to 2,396), which might 339 
depend on the sequencing, or some of the differences might be explained because B. 340 
breve may have megaplasmids or contain large chromosomally integrated elements 341 
(~200 Kb) (Bottacini et al., 2015). The pan-genome of 55 strains was determined as a 342 
not fully closed but gradually saturated pan-genome, which was consistent with 343 
Bottacini et al. (2014, 2018). But the difference between current and previous results 344 
was the number of core-genes and total genes, in which t e core-gene size previously 345 
calculated for 74 B. breve strains (1,282 gene families) was just slightly larger than 346 
the current 55 representatives (1,111 gene families). On the other hand, the calculated 347 
pan-genome size for 74 B. breve strains (6,138 gene families) was smaller than those 348 
55 strains (6,707 gene families). A possible reason was that the origin of the current 349 
strains were only from children (Bottacini et al., 2018). 350 
MCL comparative genomic analysis showed that B. breve species had high genomic 351 
diversity. The strain with the largest difference in gene content was FFHNFQ49M1, 352 
which had the highest numbers of truly unique genes (TUGS). Based on comparative 353 
genomic analysis of 73 B. breve strains, most of the variome (the genetic variability) 354 
in the strain composed of TUGS, and the predictive function of TUGS indicated that 355 
at least 50% of the genes could encode uncharacterized, hypothetical proteins, or 356 
mobile genetic elements (Bottacini et al., 2018a). Species diversity and the ability to 357 
metabolize large amounts of carbohydrates were thoug t to be the results of 358 
horizontal gene transfer and gene duplication (Kim et al., 2013). In addition, B. breve 359 
from the same sample did not congregate according to the phylogenetic tree, such as 360 
FFGZ18I1M1 and FFGZ18I1M6, and FFGZ19I1M4 and FFGZ19I1M6, indicating 361 
different genes might be involved in carbohydrate mtabolism and antibiotic 362 
resistance, which may be the reason for the host adapt bility of the strain. 363 
Bifidobacteria could utilize a diverse range of dietary carbohydrates which were not 364 
digested in the upper intestine (O’Callaghan and van Sinderen, 2015; 365 
O’Connell-Motherway et al., 2011a). Pan-genome analysis made it possible for 35 366 
GH families to participate in the prediction of carbohydrate metabolism. Most of the 367 
carbohydrates, from milk and milk-derived foods present in an infant's diet until 368 
weaning (Arslanoglu et al., 2008), were the substrates of β-galactosidase (GH42, 369 
GH2). In the process of transitioning from a milk-based diet to solid food (around 6 370 
months), starch related carbohydrates in mashed potatoes, noodles or rice, might 371 
constitute a rich matrix for the growth of Bifidobacteria in the large intestine (Paturi et 372 
al., 2012). The current results were also consistent with those circumstances, for 373 
instance, the existence of a lot of genes encoding GH13 (α-amylase), GH3 374 
(β-glucosidase) and GH38 (α-mannosidase). 375 
Oligosaccharides are the third largest component in breast milk after lactose and fat, 376 
and more than 200 different types of oligosaccharides in breast milk have been 377 
identified in which 2’-FL is the most abundant type of HMOS (Bode, 2012; 378 
Vandenplas et al., 2018). The results showed that 36 out of 46 strains showed limited 379 
growth with 2’-FL as the sole carbon source. It was reported that two ABC transporter 380 
permeases and the fucosidase gene were adjacent to the substrate binding protein 381 
(SBP), and gene cluster for 2’-FL utilization which was consistent with previous 382 
research (Matsuki et al., 2016). The SBP gene showed a substantial role in 383 
determining the strain with fucosyllactose (2’-FL, 3’-FL) degradation ability. The 384 
presence of fucosidase genes (GH95 and GH29) confirmed that strains with vigorous 385 
growth in HMOS as the sole carbon source had one fucosidase gene. According to the 386 
glycoside hydrolase gene sequence of B. breve, it was speculated that the glycosidase 387 
was located intracellularly, and the gene sequence was homologues to that in B. 388 
longum subsp. infantis (Ruiz-Moyano et al., 2013). The metabolic pathway of HMOS 389 
by B. breve might be similar to that in B. longum subsp. infantis. The ability to utilize 390 
2’-FL by Bifidobacteria might affect the development of intestinal microbes in infants, 391 
ultimately producing beneficial effects (Ruiz-Moyano et al., 2013), which might be 392 
the reason for the high abundance of B. breve in the children’s intestine, especially in 393 
the breast-fed children. 394 
XOS could be directly used in the large intestine by Bifidobacteria, promoting the 395 
proliferation of Bifidobacteria and producing a variety of organic acids, thus helping 396 
the host to inhibit pathogenic bacteria and having a probiotic role. According to the 397 
literature (Bragatto et al., 2013), GH43 could have n important role in hydrolyzing 398 
XOS. First, XOS was transported into cells by the LacI family transcriptional 399 
regulator and substrate binding protein, and then dgraded into xylobiose and 400 
xylotriose by intracellular β-1,4-xylosidase (GH43) for further metabolism, ultimately 401 
promoting bacterial cell proliferation and producing a variety of organic acids. Most 402 
strains where GH43 was found were isolated from mixed-fed children, such as 403 
FHuNCS6M1, FFJND26M5, FJSWX23M8, FJSWX26M5, FJSWX17M  and 404 
FBJCP1M6. As a plant-derived bifidus factor, XOS could promote the proliferation of 405 
B. breve in children’s gut with the diversification of children’s diet. 406 
Research on the sensitivity of microbes to antibiotics is mainly to explore the changes 407 
of antibiotics in the intestinal microbiota, and the research on drug sensitivity of 408 
Bifidobacteria is also the basis for the development of live bacterial preparations. The 409 
important mechanism of tetracycline resistance is the result of the active drug efflux 410 
system encoded by the t t gene. Those strains showed a certain degree of tolerance 411 
associated with the existence of the et gene, and MIC values of most strains were 2 412 
μg/mL. However, the results of Duranti et al. (2016) were 0.5 μg/mL. FFJND2M11 413 
was isolated from a child who had taken a commercial probiotics product (“Miami”, 414 
Hanmi Pharmaceutical Co. Ltd., Seoul, Korea), which only contained Enterococcus 415 
faecium and Bacillus subtilis. As enterococci are often resistant to tetracycline, the 416 
resistance had the potential risk to be a lateral gene transfer to other bacteria in vivo. 417 
Penicillin-binding protein (PBP) mutations confer resistance to ampicillin 418 
(Campedelli et al., 2018), when PBP was changed, β-lactam could not bind to the cell 419 
wall of the strain, and the strain finally developed r sistance. In the current work, 56% 420 
of B. breve showed higher tolerance, which was different from a previous report 421 
(Fouhy et al., 2013). One of the antibacterial mechanisms for fluoroquinolones is to 422 
inhibit DNA gyrase (gyrA) and topoisomerase IV (parC), disturb DNA replication 423 
and kill the bacterial strain. The strains assayed (59%) were sensitive, which was 424 
consistent with previous clinical data (Jose et al., 2014). The aminoglycoside 425 
modifying enzyme is a passivating enzyme that inactv tes aminoglycoside antibiotics, 426 
and the inactivated enzymes are AAC, ANT and APH. Among them, APH has the 427 
highest resistance to antibacterial drugs (Fouhy et al., 2013). A passivation enzyme 428 
produces different drug resistant phenotypes. An aminoglycoside could be inactivated 429 
by one or more enzymes, and several aminoglycosides could be simultaneously 430 
inactivated by the same enzyme. Forty-six percent of the strains were resistant to 431 
gentamicin, which was roughly in line with a previous report (Jose et al., 2014). 432 
Chloramphenicol antibiotics act on the 50S subunit of the bacterial ribonucleoprotein 433 
and block the synthesis of proteins (Campedelli et al., 2018). In the annotation results 434 
for B. breve, the ATP-binding cassette ribosome protective proteins and antibiotic 435 
target protection were found in predicted strains, consequently, and those B. breve 436 
strains showed drug resistance to a certain degree. Furthermore, the resistance gene in 437 
Bifidobacterium may be due to the co-evolution of the microbial-host (Gibson et al., 438 
2015). Although there was little difference in the number of genes involved in the 439 
various antibiotics resistance predicted in the strain, phenotypes differed, possibly as a 440 
result of host specificity. The current results ledto a preliminary understanding of the 441 
resistance mechanism ofB. breve, which provides a research basis for the next step442 
which is the prevention and treatment of drug-induced bacteria.  443 
 444 
5. Conclusions 445 
Comparative genomics and functional analysis of 46 B. breve strains has been 446 
completed. Combined with pan-genome and core-genome, functional genome 447 
analysis allowed the identification of the genes reponsible for strain diversity and 448 
host specificity. Different gene families of different strains could serve as the basis for 449 
gene-trait matching phenotype studies. The 46 strains of B. breve strains isolated from 450 
Chinese children represented many different phenotypes, providing further 451 
information on the meanings of the genetic diversity in the species, especially the 452 
carbohydrate utilization capabilities and antibiotic resistance.  453 
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Figure captions 658 
Fig. 1 Comparative analysis of B. breve genomes.  659 
A) Venn diagram showing core-gene families and the genes specific to the B. breve 660 
strains.  661 
B) Hierarchical clustering heat map suggesting the variability of B. breve according to 662 
presence or absence of gene families.  663 
C) Pie chart displaying the percentage of dispensable and core gene families.  664 
D) ANI of 55 strains. 665 
 666 
Fig. 2 Pan-genome and core-genome of the B. breve species.  667 
A) Trend diagram of pan-genome and core-genome of Bifidobacterium breve. B) 668 
Functional distributions of the B. breve core genome.  669 
Each letter standing for the following function: [A]: RNA processing and 670 
modification, [G]: Carbohydrate transport and metabolism, [C]: Energy production 671 
and conversion, [D]: Cell cycle control, cell division, chromosome partitioning, [E]: 672 
Amino acid transport and metabolism, [F]: Nucleotide transport and metabolism, [H]: 673 
Coenzyme transport and metabolism, [I]: Lipid transport and metabolism, [J]: 674 
Translation, ribosomal structure and biogenesis, [K]: Transcription, [L]: Replication, 675 
recombination and repair, [M]: Cell wall/membrane/env lope biogenesis, [O]: 676 
Post-translational modification, protein turnover, chaperones, [P]: Inorganic ion 677 
transport and metabolism, [Q]: Secondary metabolites biosynthesis, transport, [R]: 678 
General function prediction only, [S]: Function unknown, [T]: Signal transduction 679 
mechanisms, [U]: Intracellular trafficking, secretion, and vesicular, [V]: Defense 680 
mechanisms. 681 
Fig. 3 Phylogenetic analysis of B. breve.  682 
Phylogenetic supertree showing the relationship among 55 B. breve strains and B. 683 
bifidum S17, B. bifidum PRL2010 and B. longum ATCC15697 as outliers. Strains 684 
isolated from Henan (green): FSXR13, FHuNan2016497, FHuNan2016415, 685 
FFHNXY43M2, FFHNXY26M4, FFHNFQ4M7, FFHNFQ49M1, FHeNJZ9M1, 686 
FHeNJZ2M1 and FHeNJZ1M1; Fujian (pink): FFJND6M1, FFJND2M11, 687 
FFND12M6, FFJND14L2 and FFJND26M5; Guangdong (purple): FFGZ3I1M6, 688 
FFGZ23I1M6, FFGZ19I1M6, FFGZ19I1M4, FFGZ18I1M1 and FFGZ18I1M6; 689 
Xinjiang (blue): FCJ951, FCJ1041 and FCJ653; Beijing (orange): FFBJHD5M2, 690 
FFBJCP2M1, FBJSJS1M2 and FBJCP1M6; Anhui (cyan): FAHWH9M5 and 691 
FAHWH21M7; Zhejiang (yellow): FZJHZ13M2, FZJHZ24M9, FZJHZ3M2, 692 
FZJHZ7M2 and FZJHZD20M12; Jiangsu (black): FJSWX5M4, FJSWX4M9, 693 
FJSWX39M4, FJSWX34M6, FJSWX26M5, FJSWX24M2, FJSWX23M8 and 694 
FJSWX17M1; Hunan (brown): FHuNCS6M1, FHuNCS3M4 and FHuNCS1M5. 695 
Hyphen representing other strains from NCBI. Star representing feeding method: 696 
mixed feeding (red), breast-milk (yellow), formula milk (green). Triangle representing 697 
age: ~0-6 months (red), ~6-12 months (yellow), ~1-5 years old (green). 698 
Fig. 4 The predicted glycometabolism gene in B. breve.  699 
A) Pie chart showing the predicted carbohydrate-active enzymes.  700 
B) Heat map of the predicted GH family. 701 
Fig. 5 Heat map of carbohydrate metabolism in 46 B. breve strains based on 20 702 
different substrates.  703 
Yellow for utilization; Black for non-utilization. 704 
Fig. 6 Predicted carbohydrate utilization clusters  705 
The locus map (A-G) showing that gene clusters may be involved in the utilization of 706 
various carbohydrates by certain B. breve strains. 707 
Fig. 7 Resistance genes and phenotypes of B. breve.  708 
A) The predicted resistance gene(s).  709 
B) Tolerance and sensitivity of the 46 strains to antibiotics. Red for sensitivity; Black 710 
for tolerance. 711 














FFJND14L2 Fujian 1yr; MF 2.26 2010 54 58.87 31 SAMN13258891 
FFJND2M11 Fujian 5m; MF 2.26 2017 55 58.30 41 SAMN13258892 
FFJND6M1 Fujian 7m; MF 2.30 2065 53 58.77 40 SAMN13258893 
FFJND12M6 Fujian 6m; MF 2.23 1939 55 58.66 50 SAMN13258894 
FFJND26M5 Fujian 8m; MF 2.24 1902 53 58.56 521 SAMN13258895 
FFGZ3I1M6 Guangdong 7d; FM 2.28 1982 56 58.61 77 SAMN13258896 
FFGZ18I1M6 Guangdong 7d; BM 2.26 2023 53 58.86 36 SAMN13258897 
FFGZ18I1M1 Guangdong 7d; BM 2.26 2020 51 58.86 36 SAMN13258898 
FFGZ19I1M4 Guangdong 7d; BM 2.26 2022 57 58.86 34 SAMN13258899 
FFGZ19I1M6 Guangdong 7d; BM 2.29 2001 54 59.01 31 SAMN13258900 
FFGZ23I1M6 Guangdong 7d; FM 2.34 2037 56 59.04 59 SAMN13258901 
FZJHZ13M2 Zhejiang 2m; BM 2.26 2033 53 58.87 35 SAMN13258902 
FZJHZ24M9 Zhejiang <1yr; ND 2.27 1979 53 58.63 29 SAMN13258903 
FZJHZ7M2 Zhejiang <1yr; ND 2.30 2018 56 58.77 56 SAMN13258904 
FZJHZ3M2 Zhejiang <1yr; ND 2.38 2099 60 58.95 48 SAMN13258905 
FZJHZD20M12 Zhejiang 3yr; ND 2.46 2190 69 58.30 97 SAMN13258906 
FAHWH9M5 Anhui 6m; ND 2.31 1993 53 58.91 202 SAMN13258907 
FAHWH21M7 Anhui 4m; ND 2.27 1936 54 58.67 416 SAMN13258908 
FCJ951 Xinjiang 11m; ND 2.33 2058 53 58.83 53 SAMN13258909 
FCJ653 Xinjiang 5yr; ND 2.33 2065 54 58.72 54 SAMN13258910 
FCJ1041 Xinjiang 2yr; ND 2.38 2101 52 59.06 62 SAMN13258911 
FBJSJS1M2 Beijing 9m; FM 2.35 2053 54 58.93 38 SAMN13258912 
FFBJHD5M2 Beijing 10m; BM 2.24 1898 54 58.71 176 SAMN13258913 
FBJCP1M6 Beijing 10m; MF 2.46 2190 74 58.72 304 SAMN13258914 
FFBJCP2M1 Beijing 5m; BM 2.40 2083 54 58.95 276 SAMN13258915 
FJSWX4M9 Jiangsu 10m; BM 2.31 2011 52 59.00 334 SAMN13258916 
FJSWX5M4 Jiangsu 11m; MF 2.36 2033 53 58.84 479 SAMN13258917 
FJSWX17M1 Jiangsu 6m; MF 2.36 2056 55 58.90 332 SAMN13258918 
FJSWX23M8 Jiangsu 10m; MF 2.22 1882 55 58.61 179 SAMN13258919 
FJSWX24M2 Jiangsu 6m; MF 2.26 1945 53 58.89 277 SAMN13258920 
FJSWX26M5 Jiangsu 6m; MF 2.64 2396 72 59.32 289 SAMN13258921 
FJSWX34M6 Jiangsu 5m;ND 2.46 2213 51 58.84 64 SAMN13258922 
FJSWX39M4 Jiangsu 3d; ND 2.28 1961 52 58.61 66 SAMN13258923 
FHeNJZ1M1 Henan 10m; ND 2.38 2099 54 58.86 54 SAMN13258924 
FHeNJZ2M1 Henan <1yr; ND 2.37 2103 71 58.54 45 SAMN13258925 
FHeNJZ9M1 Henan 5m; ND 2.36 2074 55 58.82 41 SAMN13258926 
FFHNFQ4M7 Henan 8m; ND 2.27 2025 54 58.93 51 SAMN13258927 
FFHNFQ49M1 Henan 8m; ND 2.29 2048 55 58.79 28 SAMN13258928 
FFHNXY43M2 Henan 2yr; ND 2.16 1848 55 58.58 33 SAMN13258929 
FFHNXY26M4 Henan 1yr; ND 2.28 1979 55 58.78 100 SAMN13258930 
FHuNan2016497 Henan 4ys; ND 2.27 2047 57 58.82 34 SAMN13258931 
FHuNan2016415 Henan 3yr; ND 2.42 2273 75 58.68 33 SAMN13258932 
FSXR13 Henan 1yr; ND 2.57 2395 71 58.48 319 SAMN13258933 
FHuNCS1M5 Hunan <1yr; ND 2.51 2279 69 58.75 66 SAMN13258934 
FHuNCS3M4 Hunan <1yr; ND 2.38 2118 55 58.81 68 SAMN13258935 
FHuNCS6M1 Hunan <1yr; MF 2.58 2348 69 59.40 62 SAMN13258936 
UCC2003 Ireland [27] Infant faeces 2.42 1854 54 58.70 1 SAMN02604112 
12L Unpublished  Human milk  2.24 1765 52 58.90 1 SAMN03081478 
31L Unpublished Human milk  2.27 1814 53 58.60 4 SAMN02951889 
CECT7263 Spain [28] Human milk  2.33 2053 53 58.90 34 SAMN06473336 
NCFB2258 Unpublished Infant intestine 2.32 1834 53 58.70 1 SAMN03081481 
ACS-071-V-Sch8b Unpublished Human vagina  2.33 1826 53 58.70 1 SAMN00100758 
689b Unpublished Infant feces 2.33 1821 53 58.70 1 SAMN03081482 
S27 Unpublished Infant feces 2.29 1748 53 58.70 1 SAMN03081483 
JCM7017 [29] Infant feces 2.29 1770 54 58.70 2 SAMN03081479 
MF: mixed feeding (breastmilk-based added to complementary foods or formula milk); BM: breast-milk; FM: formula milk; ND: 
not determined or unknown.  
Table 2 MIC of different antibiotics for B. breve. 
Strain 
Concentration (μg/ml) 
Tet Cm Cip Amp Gm Van 
FJSWX4M9 2 16 32 0.0625 32 4 
FJSWX26M5 0.5 2 16 0.0625 64 4 
FJSWX39M4 2 2 4 4 16 0.25 
FJSWX17M1 0.125 32 8 0.0625 64 16 
FJSWX34M6 4 8 8 4 256 1 
FJSWX5M4 1 4 4 0.125 4 2 
FJSWX23M8 0.5 4 4 0.5 64 4 
FJSWX24M2 0.5 8 8 0.125 64 8 
FFJND12M6 2 8 32 8 32 0.5 
FFJND2M11 2 2 16 0.5 32 0.25 
FFJND14L2 0.5 2 16 0.5 64 0.25 
FFJND26M5 1 32 64 0.0625 16 0.25 
FFJND6M1 4 2 4 2 16 0.25 
FFBJCP2M1 2 2 32 0.0625 16 0.25 
FBJCP1M6 16 32 128 0.0625 32 16 
FFBJHD5M2 0.25 32 128 0.0625 8 16 
FBJSJS1M2 64 2 16 8 256 0.25 
FFHNFQ4M7 1 8 64 0.0625 8 4 
FFHNFQ49M1 8 8 32 0.0625 4 0.25 
FAHWH9M5 1 4 16 0.0625 2 16 
FAHWH21M7 1 16 8 0.0625 16 4 
FHuNan2016497 2 4 32 8 16 0.25 
FHeNJZ1M1 2 2 8 8 8 0.25 
FHeNJZ2M1 64 4 4 8 8 0.25 
FHeNJZ9M1 2 16 8 2 8 0.25 
FHuNan2016415 2 16 32 8 16 0.5 
FHuNCS1M5 4 0.5 4 4 4 0.25 
FHuNCS3M4 1 8 32 8 32 0.25 
FHuNCS6M1 2 8 8 4 2 0.25 
FFHNXY26M4 0.5 4 8 4 4 0.25 
FZJHZ7M2 32 16 32 8 8 0.5 
FZJHZ24M9 2 2 8 8 16 0.25 
FZJHZ13M2 0.5 2 4 1 16 1 
FZJHZ3M2 2 16 4 4 32 1 
FZJHZD20M12 4 2 16 8 256 0.25 
FCJ653 2 8 4 8 64 0.25 
FCJ1041 64 8 4 2 16 0.5 
FCJ951 2 4 8 16 16 0.25 
FSXR13 4 2 16 8 256 0.25 
FFHNXY43M2 0.5 2 0.5 4 256 0.25 
FFGZ18I1M1 32 16 4 16 128 0.5 
FFGZ18I1M6 0.5 2 4 4 128 0.25 
FFGZ19I1M4 0.5 2 4 4 64 0.25 
FFGZ23I1M6 2 2 8 16 16 0.25 
FFGZ19I1M6 0.5 1 4 8 64 0.25 
FFGZ3I1M6 0.5 1 0.25 8 16 0.25 
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